Cell-based Therapy
2 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Scooped by Nancy Parenteau
Scoop.it!

Recognizing the Disruptive Potential of Cancer Immunotherapy

Recognizing the Disruptive Potential of Cancer Immunotherapy | Cell-based Therapy | Scoop.it
Looking ahead over the coming months, there is reason for optimism regarding the next wave of phase 3 results from ongoing cancer vaccine trials.
Nancy Parenteau's insight:

Good sci/business overview of the current near-term activity in cancer immunotherapy.

more...
No comment yet.
Rescooped by Nancy Parenteau from Lung Cancer Research Digest
Scoop.it!

Trial Watch: Adoptive cell transfer for anticancer immunotherapy

Trial Watch: Adoptive cell transfer for anticancer immunotherapy | Cell-based Therapy | Scoop.it

"Following up the Trial Watch that we published on this topic in the third issue of OncoImmunology (May 2012), here we summarize the latest developments in ACT research, covering both high-impact studies that have been published during the last 13 months and clinical trials that have been initiated in the same period to assess the antineoplastic profile of this form of cellular immunotherapy."


Via Cancer Commons
more...
Cancer Commons's curator insight, March 20, 2013 6:00 PM
Vacchelli E, Eggermont A ... Kroemer G, Galluzzi L. OncoImmunology. May 2013.
Cancer Commons's curator insight, March 20, 2013 6:00 PM

Vacchelli E, Eggermont A ... Kroemer G, Galluzzi L. OncoImmunology. May 2013.

Cancer Commons's curator insight, March 20, 2013 6:01 PM

Vacchelli E, Eggermont A ... Kroemer G, Galluzzi L. OncoImmunology. May 2013.

Scooped by Nancy Parenteau
Scoop.it!

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study

Novel Two-Step Immunotherapy Shows Promise in Early-Stage Ovarian Cancer Study | Cell-based Therapy | Scoop.it
A two-step immunotherapy approach consisting of adoptive T-cell therapy and a dendritic cell vaccine has shown activity in a phase I advanced ovarian cancer clinical trial.
more...
No comment yet.